valacyclovir / Generic mfg. - LARVOL DELTA

Multidisciplinary approach for a patient with morbid obesity and psychological issues led from the pharmacy office (PubMed, Farm Comunitarios) - "Take metformin, rosuvastatin, and anastrozole...In the emergency department, he undergoes an ultrasound and intravenous analgesics that relieve the pain, diagnoses nephritic colic and prescribes metamizole and tramadol/paracetamol...The pharmacist makes a second referral to the doctor, with a written communication of suspicion of Herpes Zoster, the doctor accepts the intervention and changes the treatment by putting Valacyclovir, paracetamol/codeine and capsaicin cream. The patient returns to the pharmacy reporting that the doctor was surprised that it was a pharmacist who gave the correct diagnosis."

Journal • Breast Cancer • Diabetes • Dyslipidemia • Genetic Disorders • Herpes Zoster • Metabolic Disorders • Obesity • Oncology • Pain • Solid Tumor • Varicella Zoster

PrTK03: Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (clinicaltrials.gov) - P3 | N=711 | Active, not recruiting | Sponsor: Candel Therapeutics, Inc. | Trial completion date: Dec 2024 ➔ Dec 2030 | Trial primary completion date: Dec 2024 ➔ Aug 2024

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Candel Therapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) (clinicaltrials.gov) - P2 | N=187 | Active, not recruiting | Sponsor: Candel Therapeutics, Inc.

Trial completion date • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Adherence to Bell's Palsy Clinical Practice Guidelines: A Nationwide Retrospective Analysis (AAO-HNSF 2025) - "Data collected included the administration of corticosteroids within 72 hours, the use of antivirals (valacyclovir or acyclovir), and whether imaging or serology testing was performed. A greater percentage of patients with Bell's palsy received steroid treatment within 72 hours of symptom onset after the CPG publication. However, providers continue to order imaging and labs which are not recommended by the CPG."

Adherence • Clinical guideline • Retrospective data • CNS Disorders • Lyme Disease • Otorhinolaryngology

Adherence to Bell's Palsy Clinical Practice Guidelines: A Nationwide Retrospective Analysis (AAO-HNSF 2025) - "Data collected included the administration of corticosteroids within 72 hours, the use of antivirals (valacyclovir or acyclovir), and whether imaging or serology testing was performed. A greater percentage of patients with Bell's palsy received steroid treatment within 72 hours of symptom onset after the CPG publication. However, providers continue to order imaging and labs which are not recommended by the CPG."

Adherence • Clinical guideline • Retrospective data • CNS Disorders • Lyme Disease • Otorhinolaryngology

Single-Step Universal First-Trimester Cytomegalovirus Screening and Valacyclovir Prophylaxis in Pregnancy: A Cost-Utility Analysis in a High Seroprevalence Setting. (PubMed, Prenat Diagn) - "Although the ICER of universal CMV screening appears high in absolute terms, it compares favorably with ICER of commonly offered antenatal screening methods such as first trimester non-invasive prenatal testing for women at intermediate risk of Trisomy 21. Universal screening has the potential for averting childhood morbidity at birth and by 5-years-old. Important variables influencing the ICER include the effectiveness of valacyclovir in preventing vertical transmission, prevalence of primary CMV infection, probability of symptomatic cCMV after periconception primary infection and cost of serology tests."

HEOR • Journal • Alzheimer's Disease • Cognitive Disorders • Cytomegalovirus Infection • Infectious Disease • Otorhinolaryngology

Health resource use and epidemiologic profile of herpes zoster outpatients aged 50 years or older: a modified Delphi consensus panel in Brazil. (PubMed, Braz J Infect Dis) - "Acyclovir (95 %) and valaciclovir (80 %) were the therapy of choice in the public and private systems, respectively. Pain management included dipyrone and codeine (63 %), pregabalin (58 %), and gabapentin (Neurontin) (48 %). Our results report significant healthcare resource utilization by elderly HZ patients in Brazil."

Journal • Herpes Zoster • Neuralgia • Ophthalmology • Pain • Varicella Zoster

Polymerase chain reaction in viral anterior uveitis with secondary glaucoma: Analysis of 28 eyes from a tertiary eye care center in South India. (PubMed, Taiwan J Ophthalmol) - "PCR enables timely and accurate detection of virus causing anterior uveitis and helps salvage vision in secondary glaucoma with appropriate antiviral therapy."

Journal • Polymerase Chain Reaction • Cytomegalovirus Infection • Glaucoma • Herpes Simplex • Herpes Zoster • Ocular Inflammation • Ophthalmology • Uveitis • Varicella Zoster

CANCEL STROKE ALERT: VALACYCLOVIR TOXICITY AND ARTERIOVENOUS FISTULA MIMICKING ACUTE STROKE (CHEST 2025) - No abstract available

Cardiovascular

A Dose Too Far: Valacyclovir's Surprising Side Effect. (PubMed, Cureus) - "Valacyclovir, a prodrug of acyclovir, is a widely prescribed antiviral medication known for its efficacy in treating herpes infections. Importantly, such adverse effects have been documented even in patients with normal renal function. Given that valacyclovir's pharmacokinetics are significantly altered in individuals with renal impairment - characterized by reduced clearance and prolonged half-life - the risk of drug accumulation and subsequent neurological complications is heightened in this population. Here, we present a unique case of valacyclovir-induced psychosis in a patient with pre-existing renal failure, emphasizing the importance of considering renal function when prescribing and monitoring this medication to mitigate the risk of psychiatric complications."

Adverse events • Journal • Chronic Kidney Disease • CNS Disorders • Herpes Simplex • Infectious Disease • Nephrology • Psychiatry • Renal Disease

Burning mouth syndrome responsive to trial of fremanezumab: A case report (AHS 2025) - "Medications tried without improvement and/or discontinued due to adverse effects include nortriptyline, gabapentin, caffeine, zinc supplementation, alpha-lipoic acid, clonazepam, pregabalin, sertraline, valacyclovir, low-dose naltrexone, topical pilocarpine, and oxycodone. This case illustrates a novel application of CGRP targeting therapies in a patient with Burning Mouth Syndrome, which can be a difficult condition to treat either due to lack of efficacy or intolerability of medications. Furthermore, this case highlights the complexities of care when a beneficial treatment is finally identified but can not be obtained due to access to care. Although CGRP involvement in migraine pathophysiology and treatment is established, its role in other pain disorders, such as Burning Mouth Syndrome, has not yet been elucidated."

Case report • Clinical • CNS Disorders • Migraine • Pain

The relationship between maternal periodontitis and congenital cytomegalovirus: A hypothetical model and therapeutic implications. (PubMed, Periodontol 2000) - "The proposed noninvasive anti-cytomegalovirus periodontal therapy is highly safe for the pregnant mother and the fetus. The anti-cytomegalovirus periodontal treatment is expected to control the mother's periodontal cytomegalovirus load and, consequently, part of the baby's congenital disease risk. Research is encouraged on the relationship between periodontal cytomegalovirus and congenital diseases."

Journal • Review • Cytomegalovirus Infection • Dental Disorders • Infectious Disease • Periodontitis

INFECTIOUS COMPLICATIONS DURING INDUCTION CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOMES AND THERAPEUTIC STRATEGIES (EHA 2025) - "Regarding viral infections, 2 cases of SARS-CoV-2 infection were documented.The most frequently used antibiotic therapy class during FEs was beta-lactams, with piperacillin-tazobactam (46.8%) and ceftazidime (4.3%). Carbapenems were used in 38.3%.Among antifungal agents, amphotericin B was used in 12.8%, fluconazole in 27.7%, and voriconazole in 19.1%. For antiviral treatment, valaciclovir was used in 10.6%.Of the 36 patients, 91.6% (n=33) underwent bone marrow evaluation after the induction phase, while 3 patients died before being evaluated... Empirical antibiotic therapy has played a major role in reducing mortality from chemotherapy-induced infections. However, the increasing emergence of MRB strains presents a significant therapeutic challenge. Our findings align closely with national and international data."

Clinical data • Retrospective data • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases

Estimating Risks of Central Nervous System Disturbance Associated with Medications for Herpes Zoster: Findings from a Regional Population-Based Cohort Study Using the Shizuoka Kokuho Database. (PubMed, Drugs Real World Outcomes) - "Acyclovir and valacyclovir, when compared with famciclovir, are associated with an increased risk of CNS disturbance in patients with herpes zoster, particularly among those with severe renal dysfunction. These findings highlight the importance of careful consideration of renal function when determining antiviral dosing and support the development of clinical guidelines to enhance the safety of antiviral treatments, though further investigation into additional kidney function stages is needed."

Journal • CNS Disorders • Herpes Zoster • Mental Retardation • Nephrology • Psychiatry • Renal Disease • Varicella Zoster

INCIDENCE AND RISK FACTORS OF HERPES ZOSTER INFECTION IN PEDIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS: A 16 YEAR STUDY (EULAR 2025) - "The median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) at herpes zoster diagnosis was 4 (IQR = 0 – 12), 16.39% had recurrent HZI, 11.48% had superimposed bacterial infection, and more than two-thirds were treated with the anti-viral acyclovir or valacyclovir (88.52%). The prevalence and incidence of HZI in cSLE is 15.72% and 38.40 per 100 person-years, respectively. Risk factors identified for HZI among cSLE were lymphopenia, lupus nephritis, and immunosuppressive agents. In particular, IV cyclophosphamide, azathioprine, and glucocorticoid dose of ≥5mg increased the risk for development of HZI by 1.61, 2.07, 10.20 times, respectively."

Clinical • Glomerulonephritis • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Pediatrics • Rheumatology • Systemic Lupus Erythematosus • Varicella Zoster

Neurotoxicity from inordinate valacyclovir dosage in an elderly woman with stage 5 chronic kidney disease. (PubMed, Br J Clin Pharmacol) - "Unadjusted doses of valacyclovir can cause neurotoxicity in patients with chronic kidney disease. Despite minimal urinary elimination her blood concentration fell from 8.8 to 0.88 mg/L with a total of 4.5 h of haemodialysis. Haemodialysis appears to be an effective method of eliminating acyclovir, especially in patients with advanced kidney disease."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth (clinicaltrials.gov) - P=N/A | N=38 | Completed | Sponsor: Tehran University of Medical Sciences

New trial • Dental Disorders • Pain • Periodontitis

A case report of Kounis syndrome type I triggered by sugammadex administration (Euroanaesthesia 2025) - "1)Case Report: We report a case of Type I KS following the administration of sugammadex, a reversal agent for rocuronium-induced neuromuscular blockade...His medical history included a valacyclovir allergy and a smoking history of 20 cigarettes/day for 15 years but no evidence of coronary artery disease, electrocardiogram (ECG) abnormalities, or exercise intolerance...In this case, rapid diagnosis and therapeutic intervention ensured a favorable outcome. ​"

Case report • Clinical • Acute Coronary Syndrome • Anesthesia • Bladder Cancer • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertension • Hypotension • Immunology • Oncology • Solid Tumor

Retrospective study of antimicrobial prophylaxis and infections in patients with acute myeloid leukemia. (ASCO 2025) - "The most common induction therapies were 7 + 3 (63.5%), azacitidine (11.1%), azacitidine + venetoclax (6.3%), and 7 + 3 + midostaurin (4.8%). 55/63 (87.3%) patients received fungal prophylaxis, usually posaconazole (n = 47)...47/63 (74.6%) patients received viral prophylaxis with acyclovir or valacyclovir... In this single-center retrospective study, fungal and viral prophylaxis were used in most patients, whereas bacterial prophylaxis was rare. Bacterial infections were frequently encountered with a high rate of bacteremia. Aspergillus was the most common fungal pathogen, reinforcing the importance of mold-active fungal prophylaxis."

Retrospective data • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer. (ASCO 2025) - P3 | "CAN-2409 is a replication-defective adenovirus encoding the HSV-tk gene that, when combined with valacyclovir (prodrug), results in immunogenic cell death. In this randomized, double-blind, Phase 3 trial, CAN-2409 significantly reduced the risk of PrCa recurrence or death when added to SoC EBRT+/- ADT. The addition of CAN-2409 was not associated with significant added toxicity. These data represent the first potentially new therapy for patients with intermediate and high risk PrCa in over 20 years."

Clinical • Combination therapy • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Adenovirus Vasculitis with Necrotising Retinitis and Schisis-Associated Macular Edema (SAME): A Rare Primary Manifestation of HIV-Related Immunodeficiency. (PubMed, Ocul Immunol Inflamm) - "Initial treatment involved topical corticosteroids, intravitreal ganciclovir, and systemic valganciclovir. Due to disease progression, therapy was subsequently escalated to high-dose valacyclovir (2 g TID) with intravitreal ganciclovir and later intravenous cidofovir was introduced...Adenoviral necrotizing retinitis remains an underrecognized entity, particularly in immunocompromised patients. This case underscores the importance of PCR testing for HAdV in atypical necrotizing retinitis and highlights the need for a combined treatment approach, including systemic and intravitreal antiviral therapy."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Macular Edema • Ocular Inflammation • Ophthalmology • Retinal Disorders • Vasculitis • CD4

Valacyclovir-induced neurotoxicity and nephrotoxicity in an elderly patient with a history of nephrectomy: a case report. (PubMed, BMC Nephrol) - "This case report demonstrates a rare case of acute kidney injury due to an exaggerated response to valacyclovir-induced crystal nephropathy, presenting in tandem with valacyclovir-induced neurotoxicity, which has only been described in three case reports. This case highlights the importance of careful history and physical exam to facilitate a more accurate and timely diagnosis, especially in patients with a history of nephrectomy."

Journal • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Hematological Disorders • Herpes Simplex • Herpes Zoster • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Pain • Renal Calculi • Renal Disease • Thrombocytopenic Purpura • Type 2 Diabetes Mellitus • Varicella Zoster

Valacyclovir in Pain Management of Acute Apical Abscesses (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of California, San Francisco | N=250 ➔ 60 | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: May 2024 ➔ Dec 2025

Enrollment change • Trial completion date • Trial primary completion date • Pain

Synthesis, characterization and antiviral efficacy of Valacyclovir loaded polymeric nanoparticles against wild-type Herpes Simplex Virus type 2. (PubMed, Biomed Mater) - "The results demonstrated that the valacyclovir-loaded nanoparticles exhibited a 1.2-1.3-fold increase in antiviral efficacy compared to the free drug. This study thus presents a novel nanotechnology-based treatment approach for HSV-2, offering enhanced antiviral effectiveness over traditional treatments.&#xD."

Journal • Herpes Simplex